– USA, MI – Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced the appointment of Craig Thompson to its Board as an Independent Director, bringing the Board to eight members.
About Craig Thompson
Craig Thompson has been CEO and a member of the board of directors at Cerevance, a clinical-stage biotechnology company focused on neurodegenerative, psychiatric, and CNS-controlled metabolic disorders, since April 2022. Mr. Thompson is also currently a member of the board of directors of NervGen Pharma Corp, a clinical-stage biotechnology company focused on developing therapies for neurotrauma and neurologic diseases. Mr. Thompson was previously President & CEO and a member of the board of directors of Neurana Pharmaceuticals from June 2018 to April 2022. Before Neurana, Mr. Thompson was President & CEO of Anthera Pharmaceuticals Inc. Mr. Thompson’s biotechnology leadership experience included serving as COO for Tetraphase Pharmaceuticals Inc. and as CCO for Trius Therapeutics, Inc., where he was involved in the $700+ million acquisition of Trius Therapeutics by Cubist Pharmaceuticals, Inc., and led a partnership with Bayer Pharma AG.
Before that, Craig Thompson served in various global and U.S. leadership roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Diseases, and Inflammation, and he ultimately served as Vice President of Marketing for Pfizer’s Specialty Care Business Unit.
Previous to Pfizer, Craig Thompson served in positions of increasing responsibility in global marketing at Merck & Co., where he was in product management for Zocor®, including leading the rollout of the landmark Heart Protection Study. He also was instrumental in the pre-launch planning for Vytorin® and Zetia® as part of the European partnership between Merck and Schering-Plough.
Craig Thompson holds a Bachelor of Commerce degree from McMaster University and an MBA from the University of Notre Dame.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on bringing new medicines to market that address the unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next-generation program, which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enable rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaboration, and advancement of its pre-clinical pipeline.
For more: https://www.esperion.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.